Results 111 to 120 of about 5,344,313 (296)

A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma

, 2019
More and more clinical trials have tried to assess the clinical benefit of anti-interleukin (IL)-13 monoclonal antibodies for uncontrolled asthma. The aim of this study is to evaluate the efficacy and safety of anti-IL-13 monoclonal antibodies for ...
Huiting Huang (2867504), Wenbin Cheng (6282062), Xiaohong Liu, Huiting Huang, Kai Wang (21246), Kai Wang, Hang Li (123039), Xiaohong Liu (50816), Hang Li, Wenbin Cheng   +9 more
core   +1 more source

Characterization of the Interaction between Interleukin-13 and Interleukin-13 Receptors

Characterization of the Interaction between Interleukin-13 and Interleukin-13 Receptors
論文(Article)
  +6 more sources

Clinical therapeutic effects of multi-target treatment on type-Ⅳ lupus nephritis and the effects on serum IL-6,IL-13,and IL-18 levels

Linchuang shenzangbing zazhi, 2016
Objective To investigate the clinical therapeutic effects of multi-target inductive treatment on type-Ⅳ lupus nephritis(LN) and the effects on serum interleukin-6(IL-6),IL-13,and IL-18 levels.Methods A total of 60 eligible patients with LN of Department ...
ZHANG Yong, LI Shu-peng, CHENG De-zheng, LIANG Jing   +3 more
doaj  

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

The effects of anti-interleukin-5 on SABA rescue use.

, 2016
The effects of anti-interleukin-5 on SABA rescue use.
Ting Liu (45625), Fa-Ping Wang (3358667), Hui Mao (115181), Zhu Lan (3358673), Su-Yun Li (3358670)   +4 more
core   +1 more source

Exploration of novel therapeutic targets for keloids based on clinical and molecular data: the role of the IL-4/IL-13 signaling pathway

European Journal of Medical Research
Background and Objectives Keloids are problematic fibrotic lesions with excessive collagen and chronic inflammation; their underlying causes are not fully understood.
Xueli Li, Jianping Lan, Ruoyun Liu, Tingting Lin, Zheqi Li, Bo Cheng   +5 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Cholinergic Urticaria, an Effective and Safe “Off Label” Use of Dupilumab: A Case Report with Literature Review

Clinical, Cosmetic and Investigational Dermatology, 2022
Maria Maddalena Sirufo,1,2 Alessandra Catalogna,1,2 Martina Raggiunti,1,2 Francesca De Pietro,1,2 Lia Ginaldi,1,2 Massimo De Martinis1,2 1Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy; 2Allergology and ...
Sirufo MM, Catalogna A, Raggiunti M, De Pietro F, Ginaldi L, De Martinis M   +5 more
doaj  

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Receptor for Interleukin 13 [PDF]

Journal of Biological Chemistry, 1995
Nicholas I. Obiri, Waldemar Debinski, Warren J. Leonard, Raj K. Puri   +3 more
openaire   +2 more sources